Biomarkers of Eosinophil Involvement in Allergic and Eosinophilic Diseases: Review of Phenotypic and Serum Markers Including a Novel Assay to Quantify Levels of Soluble Siglec-8

Overview

Journal J Immunol Methods

Publisher Elsevier

Specialties Allergy & Immunology
Pathology

Date 2012 Jun 12

PMID 22683541

Citations 19

Authors

Ho Jeong Na

Robert G Hamilton

Amy D Klion

Bruce S Bochner

Affiliations

Soon will be listed here.

Abstract

There remains considerable controversy in the management of eosinophilic disorders, mainly due to a paucity of information regarding the clinical interpretation of total blood eosinophil counts versus surface activation markers versus eosinophil-derived or eosinophil-influencing mediator levels. Regrettably, few tests have been validated that define a unique clinical or prognostic phenotype that is more useful than simply monitoring total blood eosinophil counts. In this manuscript, phenotypic (cell surface) markers, along with serum and tissue-based markers that have been examined in the context of disease activity, are reviewed. We also report the development of a novel assay for detecting soluble Siglec-8 (sSiglec-8), a protein likely derived largely from eosinophils, as a potential serum biomarker. The assay consists of a competitive ELISA using a recombinant Siglec-8-Fc fusion protein. The goal of this preliminary study was to determine if sSiglec-8 is a useful biomarker that differentiates among patients with various eosinophil-associated diseases. In the final analysis, it is fair to say that further research is sorely needed to fully understand and validate the utility of various biomarkers, including sSiglec-8, before their use in clinical practice can be recommended with confidence.

Citing Articles

Activated sputum eosinophils associated with exacerbations in children on mepolizumab.

Wilson G, Knight J, Liu Q, Shelar A, Stewart E, Wang X J Allergy Clin Immunol. 2024; 154(2):297-307.e13.

PMID: 38485057 PMC: 11305967. DOI: 10.1016/j.jaci.2024.01.031.

Eosinophils as potential biomarkers in respiratory viral infections.

Macchia I, La Sorsa V, Urbani F, Moretti S, Antonucci C, Afferni C Front Immunol. 2023; 14:1170035.

PMID: 37483591 PMC: 10358847. DOI: 10.3389/fimmu.2023.1170035.

Intestinal proline is a potential anti-allergy factor for allergy diagnosis and therapy.

Ma J, Wang C, Wang F, Zhang Y, Liu Y, Zhang J Front Nutr. 2022; 9:1036536.

PMID: 36532514 PMC: 9748422. DOI: 10.3389/fnut.2022.1036536.

Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma.

Wendlinger S, Wohlfarth J, Kreft S, Siedel C, Kilian T, Dischinger U Cancers (Basel). 2022; 14(9).

PMID: 35565423 PMC: 9104271. DOI: 10.3390/cancers14092294.

Siglec Signaling in the Tumor Microenvironment.

van Houtum E, Bull C, Cornelissen L, Adema G Front Immunol. 2021; 12:790317.

PMID: 34966391 PMC: 8710542. DOI: 10.3389/fimmu.2021.790317.

References

Koh G, Shek L, Goh D, van Bever H, Koh D . Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med. 2006; 101(4):696-705. DOI: 10.1016/j.rmed.2006.08.012. View

Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F . Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011; 128(5):989-95.e1-8. DOI: 10.1016/j.jaci.2011.07.056. View

Simon D, Wardlaw A, Rothenberg M . Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol. 2010; 126(1):3-13. PMC: 2902687. DOI: 10.1016/j.jaci.2010.01.055. View

Gibson P, Dolovich J, Girgis-Gabardo A, Morris M, Anderson M, Hargreave F . The inflammatory response in asthma exacerbation: changes in circulating eosinophils, basophils and their progenitors. Clin Exp Allergy. 1990; 20(6):661-8. DOI: 10.1111/j.1365-2222.1990.tb02705.x. View

Menzies-Gow A, Kay A, Robinson D . Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2002; 167(2):199-204. DOI: 10.1164/rccm.200208-789OC. View

Kim S, Marigowda G, Oren E, Israel E, Wechsler M . Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010; 125(6):1336-43. DOI: 10.1016/j.jaci.2010.03.028. View

Nutku E, Aizawa H, Hudson S, Bochner B . Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood. 2003; 101(12):5014-20. DOI: 10.1182/blood-2002-10-3058. View

Kayaba H, Yamada Y, Cui C, Saito N, Honda K, Kobayashi Y . Expression of VLA-4 on eosinophils decreases in patients with eosinophilia. Int Arch Allergy Immunol. 2001; 125 Suppl 1:33-7. DOI: 10.1159/000053850. View

Yoon J, Terada A, Kita H . CD66b regulates adhesion and activation of human eosinophils. J Immunol. 2007; 179(12):8454-62. DOI: 10.4049/jimmunol.179.12.8454. View

10.

Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13):1201-14. DOI: 10.1056/NEJMoa025217. View

11.

Rothenberg M, Klion A, Roufosse F, Kahn J, Weller P, Simon H . Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008; 358(12):1215-28. DOI: 10.1056/NEJMoa070812. View

12.

von Gunten S, Bochner B . Basic and clinical immunology of Siglecs. Ann N Y Acad Sci. 2008; 1143:61-82. PMC: 3902170. DOI: 10.1196/annals.1443.011. View

13.

Kay A, Klion A . Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome. Immunol Allergy Clin North Am. 2004; 24(4):645-66, vii. DOI: 10.1016/j.iac.2004.06.007. View

14.

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

15.

Jahnsen F, Brandtzaeg P, Halstensen T . Monoclonal antibody EG2 does not provide reliable immunohistochemical discrimination between resting and activated eosinophils. J Immunol Methods. 1994; 175(1):23-36. DOI: 10.1016/0022-1759(94)90328-x. View

16.

Stevens W, Kim T, Pujanauski L, Hao X, Braciale T . Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry. J Immunol Methods. 2007; 327(1-2):63-74. PMC: 2670191. DOI: 10.1016/j.jim.2007.07.011. View

17.

Tateno H, Crocker P, Paulson J . Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology. 2005; 15(11):1125-35. DOI: 10.1093/glycob/cwi097. View

18.

Nishikawa K, Morii T, Ako H, Hamada K, Saito S, Narita N . In vivo expression of CD69 on lung eosinophils in eosinophilic pneumonia: CD69 as a possible activation marker for eosinophils. J Allergy Clin Immunol. 1992; 90(2):169-74. DOI: 10.1016/0091-6749(92)90068-d. View

19.

Zimmerman B, Lanner A, ENANDER I, Zimmerman R, PETERSON C, Ahlstedt S . Total blood eosinophils, serum eosinophil cationic protein and eosinophil protein X in childhood asthma: relation to disease status and therapy. Clin Exp Allergy. 1993; 23(7):564-70. DOI: 10.1111/j.1365-2222.1993.tb00895.x. View

20.

Spergel J, Rothenberg M, Collins M, Furuta G, Markowitz J, Fuchs 3rd G . Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2011; 129(2):456-63, 463.e1-3. DOI: 10.1016/j.jaci.2011.11.044. View